The pandemic Escherichia coli sequence type 131 strain is acquired even in the absence of antibiotic exposure
Autoři:
Grant R. Whitmer aff001; Ganga Moorthy aff002; Mehreen Arshad aff001
Působiště autorů:
Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America
aff001; Department of Pediatrics, Duke University, Durham, North Carolina, United States of America
aff002; Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois, United States of America
aff003
Vyšlo v časopise:
The pandemic Escherichia coli sequence type 131 strain is acquired even in the absence of antibiotic exposure. PLoS Pathog 15(12): e1008162. doi:10.1371/journal.ppat.1008162
Kategorie:
Pearls
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1008162
Zdroje
1. Brolund A, Edquist PJ, Makitalo B, Olsson-Liljequist B, Soderblom T, Wisell KT, et al. Epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli in Sweden 2007–2011. Clin Microbiol Infect. 2014;20(6):O344–52. Epub 2013/10/15. doi: 10.1111/1469-0691.12413 24118431.
2. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis. 2010;51(3):286–94. Epub 2010/06/25. doi: 10.1086/653932 20572763.
3. Banerjee R, Johnson JR. A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother. 2014;58(9):4997–5004. Epub 2014/05/29. doi: 10.1128/AAC.02824-14 24867985; PubMed Central PMCID: PMC4135879.
4. Hilty M, Betsch BY, Bogli-Stuber K, Heiniger N, Stadler M, Kuffer M, et al. Transmission dynamics of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis. 2012;55(7):967–75. doi: 10.1093/cid/cis581 22718774; PubMed Central PMCID: PMC3436924.
5. OstholmBalkhed A, Tarnberg M, Nilsson M, Nilsson LE, Hanberger H, Hallgren A, et al. Duration of travel-associated faecal colonisation with ESBL-producing Enterobacteriaceae—A one year follow-up study. PLoS ONE. 2018;13(10):e0205504. Epub 2018/10/26. doi: 10.1371/journal.pone.0205504 30356258; PubMed Central PMCID: PMC6200250.
6. Sarkar S, Hutton ML, Vagenas D, Ruter R, Schuller S, Lyras D, et al. Intestinal colonization traits of pandemic multidrug-resistant Escherichia coli ST131. J Infect Dis. 2018;218(6):979–90. Epub 2018/02/23. doi: 10.1093/infdis/jiy031 29471349; PubMed Central PMCID: PMC6093498.
7. Lavigne JP, Vergunst AC, Goret L, Sotto A, Combescure C, Blanco J, et al. Virulence potential and genomic mapping of the worldwide clone Escherichia coli ST131. PLoS ONE. 2012;7(3):e34294. doi: 10.1371/journal.pone.0034294 22457832; PubMed Central PMCID: PMC3311635.
8. Vimont S, Boyd A, Bleibtreu A, Bens M, Goujon JM, Garry L, et al. The CTX-M-15-producing Escherichia coli clone O25b: H4-ST131 has high intestine colonization and urinary tract infection abilities. PLoS ONE 2012;7(9):e46547. Epub 2012/10/03. doi: 10.1371/journal.pone.0046547 23029548; PubMed Central PMCID: PMC3460912.
9. Stoesser N, Sheppard AE, Pankhurst L, De Maio N, Moore CE, Sebra R, et al. Evolutionary History of the Global Emergence of the Escherichia coli Epidemic Clone ST131. MBio. 2016;7(2):e02162–15. doi: 10.1128/mBio.02162-15 27006459
10. Gurnee EA, Ndao IM, Johnson JR, Johnston BD, Gonzalez MD, Burnham CA, et al. Gut Colonization of Healthy Children and Their Mothers With Pathogenic Ciprofloxacin-Resistant Escherichia coli. J Infect Dis. 2015;212(12):1862–8. Epub 2015/05/15. doi: 10.1093/infdis/jiv278 25969564; PubMed Central PMCID: PMC4655851.
11. Rodriguez-Revuelta MJ, Lopez-Cerero L, Serrano L, Luna-Lagares S, Pascual A, Rodriguez-Bano J. Duration of Colonization by Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae in Healthy Newborns and Associated Risk Factors: A Prospective Cohort Study. Open Forum Infect Dis. 2018;5(12):ofy312. Epub 2018/12/21. doi: 10.1093/ofid/ofy312 30568982; PubMed Central PMCID: PMC6293479.
12. Vading M, Kabir MH, Kalin M, Iversen A, Wiklund S, Naucler P, et al. Frequent acquisition of low-virulence strains of ESBL-producing Escherichia coli in travellers. J Antimicrob Chemother. 2016;71(12):3548–55. Epub 2016/08/28. doi: 10.1093/jac/dkw335 27566312.
13. Madigan T, Johnson JR, Clabots C, Johnston BD, Porter SB, Slater BS, et al. Extensive Household Outbreak of Urinary Tract Infection and Intestinal Colonization due to Extended-Spectrum beta-Lactamase-Producing Escherichia coli Sequence Type 131. Clin Infect Dis. 2015;61(1):e5–12. Epub 2015/04/02. doi: 10.1093/cid/civ273 25828998; PubMed Central PMCID: PMC4542914.
14. Morales Barroso I, Lopez-Cerero L, Navarro MD, Gutierrez-Gutierrez B, Pascual A, Rodriguez-Bano J. Intestinal colonization due to Escherichia coli ST131: risk factors and prevalence. Antimicrob Resist Infect Control. 2018;7:135. Epub 2018/11/27. doi: 10.1186/s13756-018-0427-9 30473785; PubMed Central PMCID: PMC6238289.
15. Liu CM, Stegger M, Aziz M, Johnson TJ, Waits K, Nordstrom L, et al. Escherichia coli ST131-H22 as a Foodborne Uropathogen. MBio. 2018;9(4). Epub 2018/08/30. doi: 10.1128/mBio.00470-18 30154256; PubMed Central PMCID: PMC6113624.
16. Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev. 2014;27(3):543–74. Epub 2014/07/02. doi: 10.1128/CMR.00125-13 24982321; PubMed Central PMCID: PMC4135899.
17. Villa L, Garcia-Fernandez A, Fortini D, Carattoli A. Replicon sequence typing of IncF plasmids carrying virulence and resistance determinants. J Antimicrob Chemother. 2010;65(12):2518–29. Epub 2010/10/12. doi: 10.1093/jac/dkq347 20935300.
18. Lanza VF, de Toro M, Garcillan-Barcia MP, Mora A, Blanco J, Coque TM, et al. Plasmid flux in Escherichia coli ST131 sublineages, analyzed by plasmid constellation network (PLACNET), a new method for plasmid reconstruction from whole genome sequences. PLoS Genet. 2014;10(12):e1004766. doi: 10.1371/journal.pgen.1004766 25522143; PubMed Central PMCID: PMC4270462.
19. Schaufler K, Semmler T, Pickard DJ, de Toro M, de la Cruz F, Wieler LH, et al. Carriage of Extended-Spectrum Beta-Lactamase-Plasmids Does Not Reduce Fitness but Enhances Virulence in Some Strains of Pandemic E. coli Lineages. Front Microbiol. 2016;7:336. Epub 2016/03/26. doi: 10.3389/fmicb.2016.00336 27014251; PubMed Central PMCID: PMC4794485.
20. Gibreel TM, Dodgson AR, Cheesbrough J, Fox AJ, Bolton FJ, Upton M. Population structure, virulence potential and antibiotic susceptibility of uropathogenic Escherichia coli from Northwest England. J Antimicrob Chemother. 2012;67(2):346–56. Epub 2011/10/27. doi: 10.1093/jac/dkr451 22028202.
21. Alqasim A, Emes R, Clark G, Newcombe J, La Ragione R, McNally A. Phenotypic microarrays suggest Escherichia coli ST131 is not a metabolically distinct lineage of extra-intestinal pathogenic E. coli. PLoS ONE. 2014;9(2):e88374. Epub 2014/02/12. doi: 10.1371/journal.pone.0088374 24516644; PubMed Central PMCID: PMC3917908.
22. Hussain A, Ranjan A, Nandanwar N, Babbar A, Jadhav S, Ahmed N. Genotypic and phenotypic profiles of Escherichia coli isolates belonging to clinical sequence type 131 (ST131), clinical non-ST131, and fecal non-ST131 lineages from India. Antimicrob Agents Chemother. 2014;58(12):7240–9. Epub 2014/09/24. doi: 10.1128/AAC.03320-14 25246402; PubMed Central PMCID: PMC4249578.
23. Sarkar S, Roberts LW, Phan MD, Tan L, Lo AW, Peters KM, et al. Comprehensive analysis of type 1 fimbriae regulation in fimB-null strains from the multidrug resistant Escherichia coli ST131 clone. Mol Microbiol. 2016;101(6):1069–87. doi: 10.1111/mmi.13442 27309594.
24. Totsika M, Beatson SA, Sarkar S, Phan MD, Petty NK, Bachmann N, et al. Insights into a multidrug resistant Escherichia coli pathogen of the globally disseminated ST131 lineage: genome analysis and virulence mechanisms. PLoS ONE. 2011;6(10):e26578. doi: 10.1371/journal.pone.0026578 22053197; PubMed Central PMCID: PMC3203889.
25. Galtier M, De Sordi L, Maura D, Arachchi H, Volant S, Dillies MA, et al. Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low impact on microbiota composition. Environ Microbiol. 2016;18(7):2237–45. doi: 10.1111/1462-2920.13284 26971586.
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2019 Číslo 12
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Coxiella burnetii Type 4B Secretion System-dependent manipulation of endolysosomal maturation is required for bacterial growth
- IL-22 produced by type 3 innate lymphoid cells (ILC3s) reduces the mortality of type 2 diabetes mellitus (T2DM) mice infected with Mycobacterium tuberculosis
- The pandemic Escherichia coli sequence type 131 strain is acquired even in the absence of antibiotic exposure
- A role of hypoxia-inducible factor 1 alpha in Mouse Gammaherpesvirus 68 (MHV68) lytic replication and reactivation from latency